Presbyopia is the age-related loss of near focusing ability that becomes noticeable to most people between 40 and 45.Three broad management paths exist: reading glasses or progressive spectacles, monovision LASIK where one eye is corrected for distance and the other for near, and refractive lens exchange with a multifocal or EDOF IOL that replaces the ageing crystalline lens entirely. Each pathway differs substantially in reversibility, optical quality, candidacy age, and long-term cost.

According to Dr. Mayank Bansal, a leading refractive surgeon at the Best Eye Hospital in Delhi, “Presbyopia correction is one area where patient lifestyle and visual expectations matter as much as the optics. A surgeon who recommends the same solution to every patient over 45 is not doing the full workup. The right answer depends on distance prescription, corneal health, age, and how the person actually uses their eyes.”

How Do the Three Options Compare?

The choice between reading glasses, monovision LASIK, and multifocal IOL involves tradeoffs across vision quality, cost, reversibility, and candidacy.

Reading glasses remain the simplest, lowest-risk option and are entirely appropriate for patients who are comfortable with them. For a full overview of refractive surgery procedures.

Who Is the Right Candidate for Each Option?

Patient selection for presbyopia correction requires honest assessment of visual demands, existing prescription, corneal health, and willingness to accept optical tradeoffs.

• Reading glasses and progressives: The appropriate choice for anyone who tolerates glasses, has no existing distance prescription requiring correction, or has corneal health that makes surgical options unsuitable. 
• Monovision LASIK or SMILE: Suited to patients aged 40 to 55 with a meaningful distance refractive error and adequate corneal thickness for laser correction. The dominant eye is corrected to emmetropia for distance and the non-dominant eye is corrected to approximately -1.25 to -1.5D for near. 
• Multifocal IOL (refractive lens exchange): The strongest indication is a presbyopic patient aged 45 or above with early lens changes, significant distance prescription, or approaching cataract. Replacing the natural crystalline lens with a multifocal, EDOF, or trifocal IOL corrects all distances simultaneously and eliminates any future cataract entirely. 
• Contraindications to multifocal IOL: Patients with significant dry AMD, diabetic maculopathy, epiretinal membrane, irregular corneal astigmatism, or occupational dependence on high-contrast night vision are generally directed toward monofocal IOLs with monovision blending rather than multifocal platforms. 
• Bilateral symmetry: For all surgical options, bilateral correction delivered at or close to the same time produces better neuroadaptation outcomes than staged procedures months apart. The visual cortex adapts faster when both eyes receive their new optical input simultaneously.

No single option dominates across all situations, and a thorough pre-operative workup separates appropriate candidates from those who will be disappointed regardless of technical surgical success. For a full breakdown of cataract surgeryl and EDOF IOL options and costs.

Why Choose Claritas Eye Hospital for Presbyopia ?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with over 15 years of refractive and cataract surgery practice including monovision LASIK, SMILE, and the full range of premium IOL platforms. Every presbyopia patient at Claritas receives corneal topography, macular OCT, dominant eye testing, and a monovision contact lens trial where applicable before any surgical option is recommended.

High myopia above -10 dioptres presents a specific challenge for refractive surgery. LASIK works by reshaping the cornea with an excimer laser, but it removes corneal tissue to do so. At high powers the amount of tissue required to achieve the correction exceeds what the cornea can safely spare. An ICL is placed inside the eye between the iris and the natural crystalline lens, correcting the refractive error without touching the cornea at all.

According to Dr. Mayank Bansal, a leading refractive surgeon at the Best Eye Hospital in Delhi,
“For anyone above -8 to -10 dioptres, ICL is not simply an alternative to LASIK it is the safer, more optically superior procedure. The cornea is left entirely untouched, and the correction is reversible if the patient’s prescription changes significantly over time.”

How Does ICL Compare to LASIK for High Myopia?

The two procedures address the same goal through fundamentally different mechanisms. That difference determines which is appropriate for any given patient and prescription.

The cost difference narrows considerably when accounting for optical outcome quality at high powers. A -12D patient achieving 6/6 uncorrected vision with excellent contrast sensitivity through an ICL gets a materially better visual result than the same patient managed at the edge of safe LASIK territory. For a full overview of all refractive surgery procedures.

Who Is the Ideal Candidate for ICL at High Myopia?

ICL candidacy is determined by anterior chamber depth, endothelial cell count, and the vault the lens will create between itself and the natural crystalline lens after implantation.

• Prescription range: The Staar EVO Plus ICL platform covers myopia from -0.5 to -20.0 dioptres with cylinder correction up to -6.0 D via the toric variant.
• Anterior chamber depth: A minimum anterior chamber depth of 2.8 mm is required to accommodate the ICL safely. 
• Endothelial cell count: ICL implantation requires adequate corneal endothelial cell density, typically above 2,000 cells per mm squared. 
• Age: ICL surgery is performed between ages 21 and 45 in most protocols. Below 21, refraction may still be changing. 
• Retinal health in high myopes: High myopia carries an intrinsically elevated risk of retinal pathology including lattice degeneration, peripheral breaks, and retinal detachment. 
• Post-ICL monitoring: Annual review of vault height, endothelial cell count, and IOP is standard practice for all ICL patients. 

The ideal ICL candidate is a high myope with adequate anterior chamber depth, a healthy endothelium, and a prescription stable for at least 12 months who wants spectacle-free vision without the irreversible corneal tissue removal that LASIK requires. For the complete pricing breakdown of ICL options including Staar EVO Plus and toric variants, read our detailed guide on ICL pricing in Delhi.

Why Choose Claritas Eye Hospital for ICL Surgery ?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with over 15 years of refractive and cataract surgery practice including ICL implantation across the full power range. Pre-operative workup for every ICL patient at Claritas includes anterior chamber depth measurement, endothelial specular microscopy, corneal topography, and dilated retinal examination before any surgical booking is confirmed.

Negative dysphotopsia is a visual phenomenon reported by a subset of patients after otherwise successful cataract surgery. Patients describe a dark arc, crescent, or shadow in the temporal peripheral visual field of the operated eye, most noticeable in bright conditions. It is distinct from positive dysphotopsia, which refers to glare, halos, and starbursts caused by light scatter off IOL edges. 

According to Dr. Mayank Bansal, a leading cataract surgeon at the Best Eye Hospital in Delhi,
“Negative dysphotopsia is one of the more difficult post-operative complaints to manage because the surgery has gone well by every objective measure, yet the patient experiences a genuinely bothersome dark shadow. Reassurance is the first step, but some cases do need intervention.”

Why Does Negative Dysphotopsia Happen?

The exact optical mechanism remains incompletely understood, but the most accepted explanation involves a gap in retinal illumination created by the optical geometry of modern small-diameter IOLs within the capsular bag.

• The IOL edge shadow theory: Modern foldable IOLs have a smaller diameter than the natural crystalline lens they replace. Light entering from the temporal periphery can bypass the IOL edge and fall on the anterior capsular rim in a pattern that creates a relative dark zone. 
• Small pupil contribution: In bright lighting conditions where the pupil constricts, the effective optical aperture narrows and the shadow from the IOL edge becomes more pronounced rather than less. 
• IOL material and refractive index: Higher refractive index IOL materials produce sharper, more defined optical edges that cast more distinct shadows compared to lower index materials. 
• Nasal retinal asymmetry: The nasal retina extends further anteriorly than the temporal retina. This anatomical asymmetry means that light entering from the temporal field illuminates a zone of retina that the IOL edge can partially shadow, whereas the nasal equivalent does not produce the same percept.
• Neuroadaptation and persistence: The majority of patients experience spontaneous resolution within 6 to 12 months as the visual cortex adapts to the altered peripheral light distribution. A minority, estimated at 1 to 3 percent of cataract patients, report persistent symptomatic negative dysphotopsia beyond one year that significantly affects quality of life.

Understanding that negative dysphotopsia is an optical consequence of IOL geometry rather than a surgical error is critical for both the surgeon explaining it and the patient trying to make sense of it. For a full overview of cataract surgery and their optical characteristics at Claritas.

What Solutions Are Available for Persistent Cases?

Most cases of negative dysphotopsia resolve without intervention. When symptoms persist beyond 12 months and significantly impact daily function, a structured escalation of management options exists.

• Watchful waiting and reassurance: The first line of management for all cases is explanation and reassurance. 
• Piggyback IOL: A secondary IOL implanted in the sulcus in front of the existing capsular bag IOL alters the optical geometry and repositions the shadow zone outside the functional visual field. 
• IOL exchange: Replacing the original IOL with a lens of different material, edge design, or optic diameter can eliminate the shadow by altering which part of the retina the edge geometry illuminates.
• Reverse optic capture: In this technique, the optic of the existing IOL is prolapsed anterior to the anterior capsule while the haptics remain in the bag. 
• Temporal YAG anterior capsulotomy: Enlarging the anterior capsulotomy at the temporal edge with YAG laser reduces the shadowing contribution of the capsular rim in the region most responsible for the percept. 

Persistent negative dysphotopsia does not signify a failed surgery, but it does require a structured management pathway rather than repeated reassurance alone. For information on refractive surgery to post-cataract visual complaints.

Why Choose Claritas Eye Hospital for Negative Dysphotopsia ?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with over 15 years of cataract and anterior segment practice including more than 12,000 cataract procedures. Pre-operative IOL selection counselling at Claritas covers optical phenomena including negative dysphotopsia, so patients understand the possibility before surgery rather than encountering it unprepared afterwards.

Diabetic patients develop cataracts earlier and more rapidly than the general population. When cataract surgery is needed in a patient with concurrent diabetic retinopathy, the approach differs meaningfully from standard phacoemulsification. Planning cataract surgery in this setting requires retinal assessment before the operation, a decision on staging versus combining procedures, and close post-operative surveillance for retinopathy progression.

According to Dr. Mayank Bansal, a leading cataract and retina surgeon at the Best Eye Hospital in Delhi,
“In a diabetic patient, the cataract and the retina are never independent problems. Removing the lens without addressing the retinal status first often leads to worse vision outcomes than the cataract itself.”

What Precautions Must Be Taken Before and During Surgery?

Pre-operative preparation in diabetic cataract patients goes beyond routine biometry. The retinal status, glycaemic control, and surgical timing all require specific assessment.

• Retinal evaluation before surgery: Dilated fundus examination and OCT must be performed before cataract surgery in every diabetic patient.
• Glycaemic optimisation: HbA1c above 8.5 percent at the time of surgery is associated with slower wound healing, increased post-operative inflammation, and faster retinopathy progression. 
• Retinopathy staging and treatment sequencing: Mild to moderate non-proliferative DR without macular edema can proceed to cataract surgery first with close retinal follow-up.
• Surgical technique modifications: Minimising surgical time, using lower phacoemulsification energy, avoiding iris trauma, and achieving a watertight wound all reduce post-operative inflammation in the diabetic eye.
• Pupil dilation: Diabetic patients commonly have poorly dilating pupils due to iris ischaemia and posterior synechiae.

The sequence of interventions matters as much as the quality of each individual procedure. For the full range of cataract surgery options and IOL types available at Claritas.

When Is a Combined Cataract and Retinal Procedure Appropriate?

In selected patients, combining cataract extraction with retinal surgery in a single anaesthetic episode offers clear advantages over staging the two procedures separately.

• Combined phaco-vitrectomy: When the cataract prevents adequate retinal assessment or treatment, combining phacoemulsification with pars plana vitrectomy in a single session allows the surgeon to remove the cataract. 
• IOL choice in combined cases: In combined phaco-vitrectomy, the capsular bag is preserved and a standard IOL is implanted.
• Post-operative surveillance after combined surgery: Anti-VEGF injections are often continued post-operatively for macular edema management. 
• When staging is still preferable: In patients with mild to moderate NPDR and no macular edema, staging cataract surgery first and reviewing the retina at one and three months post-operatively is appropriate. 

Surgery-induced inflammation is manageable and the risk of significant retinopathy acceleration is low in this subgroup.

Why Choose Claritas Eye Hospital for Cataract Surgery?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with subspecialty training in both cataract surgery and vitreoretinal surgery at AIIMS and UCLA. Over 15 years managing complex diabetic eye disease including combined phaco-vitrectomy, panretinal photocoagulation, and intravitreal injection protocols across all stages of diabetic retinopathy.

Posterior capsular opacification is the most common complication after cataract surgery, affecting up to 20 to 40 percent of patients within two years of phacoemulsification. During cataract surgery, the natural lens is removed but the thin posterior capsule that supports the IOL is left intact. Residual lens epithelial cells migrate across this capsule and proliferate, forming a cloudy membrane behind the IOL that progressively reduces vision. It is often called a secondary cataract, though it is not a recurrence of the original cataract. The capsule itself has changed, not the implanted lens.

According to Dr. Mayank Bansal, a leading cataract surgeon at the Best Eye Hospital in Delhi, “PCO is entirely treatable. YAG laser capsulotomy takes less than five minutes in the clinic, requires no incision, and restores the vision quality the patient had immediately after their cataract surgery.”

Why Does PCO Develop and Who Is at Risk?

PCO develops when lens epithelial cells left behind on the capsular rim after surgery migrate and proliferate across the posterior capsule surface. Several factors influence how quickly and severely this happens.

• Residual lens epithelial cells: Complete cortical cleanup during phacoemulsification reduces but does not eliminate the risk. Even meticulously performed surgery leaves a thin layer of cells at the capsular equator, and these are the source of subsequent migration.
• IOL material and edge design: Hydrophobic acrylic IOLs with a sharp posterior edge create a mechanical barrier that slows epithelial cell migration. Hydrophilic acrylic and PMMA lenses show higher PCO rates at two and five years, and edge design matters more than material in several published comparisons.
• Patient age: Younger patients develop PCO faster and more severely than older patients. Paediatric cataract patients have the highest rates of any age group, often developing dense opacification within weeks of surgery.
• Diabetes and uveitis: Chronic inflammation promotes faster epithelial cell proliferation. Patients with diabetic eye disease or a history of uveitis need closer post-operative monitoring for early PCO development.
• Multifocal and EDOF IOLs: Because these premium lenses are highly sensitive to optical clarity, even mild capsular haze produces disproportionate symptoms including halos, reduced contrast, and loss of intermediate clarity before standard acuity testing detects a change.

Mild haze may be visible on slit lamp examination before the patient notices any visual change, which is why structured one-year post-operative review remains useful. The decision to treat is symptom-driven and based on whether the opacification sits on the visual axis. For a full overview of the cataract surgery pathway and post-operative care.

How Is PCO Treated with YAG Laser Capsulotomy?

YAG laser capsulotomy is a non-invasive outpatient procedure that uses a neodymium-doped yttrium aluminium garnet laser to create a clear circular opening in the opacified posterior capsule. No incision is made and no anaesthetic injection is needed.

• Procedure steps: Dilating drops are instilled 20 to 30 minutes before the procedure. A contact lens is placed on the cornea for stabilisation. The YAG laser delivers a series of precisely focused pulses to disrupt the capsule membrane, creating a clear central aperture behind the IOL in 3 to 5 minutes.
• Immediate visual recovery: Most patients notice improved clarity within hours as the pupil returns to normal size. Some experience brief floaters from capsular debris, which settle within days.
• Intraocular pressure spike: IOP rises transiently in around 15 percent of patients in the hours after the procedure. Patients with pre-existing glaucoma or ocular hypertension need a pressure check one hour post-procedure and may require prophylactic IOP-lowering drops.
• IOL damage risk: The laser pulse carries a small risk of pitting the posterior IOL surface if the focal point is not set sufficiently posterior to the lens. Experienced technique and appropriate energy settings reduce this to less than 1 percent in published series.
• Retinal detachment: Disruption of the posterior capsule increases vitreous mobility and carries a low but real increased risk of retinal detachment, estimated at 0.5 to 1 percent over five years. Highly myopic patients and those with vitreoretinal history warrant fundus review before and after capsulotomy.

YAG capsulotomy at Claritas is priced at Rs 4,000 per eye a one-time, definitive treatment with no need for repeat procedures. For the complete procedure pricing schedule covering all laser and surgical treatments, read about YAG laser costs.

Why Choose Claritas Eye Hospital for Posterior Capsular Opacification?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with over 15 years of cataract and anterior segment practice including more than 12,000 cataract procedures. Post-operative follow-up at Claritas includes a structured one-year review specifically to screen for PCO and other late complications before they progress to symptomatic vision loss. International patients receive complete post-operative documentation including YAG capsulotomy records formatted for handover to their treating ophthalmologist at home. 

Astigmatism is present in roughly 40 percent of cataract patients at a clinically significant level. A standard monofocal IOL removes the cataract but leaves corneal astigmatism uncorrected, meaning the patient still needs cylindrical glasses for sharp distance vision after surgery. A toric IOL incorporates a cylindrical correction within the lens itself, aligned precisely to the steep corneal meridian during implantation. When selected and positioned correctly, it delivers spectacle-free distance vision in patients who would otherwise remain dependent on glasses despite a successful phacoemulsification.

According to Dr. Mayank Bansal, a leading cataract surgeon at the Best Eye Hospital in Delhi, “A toric IOL is not simply a premium upgrade. It is the clinically correct choice for any cataract patient with 1.0 dioptre or more of regular corneal astigmatism who wants to be free of distance glasses after surgery.”

Who Is a Candidate for a Toric IOL?

Candidacy depends on corneal topography, astigmatism type, and the absence of conditions that make precise IOL alignment unreliable.

• Regular vs irregular astigmatism: Toric IOLs correct regular astigmatism, where the cornea curves more steeply in one meridian. 
• Dry eye and biometry accuracy: Active dry eye disrupts the tear film, which degrades corneal topography readings and biometry. 
• Zonular integrity: The toric lens must stay precisely aligned in the capsular bag after surgery. 
• Pre-existing retinal or macular disease: A patient with significant diabetic maculopathy or dry AMD will not achieve the sharp distance vision a toric IOL can theoretically deliver. 
• Bilateral astigmatism: When both eyes have significant cylinder, toric IOLs in both eyes eliminate the anisometropia that arises when one eye is corrected and the other is not, producing balanced, spectacle-free binocular distance vision. 

The right IOL selection and thorough pre-operative workup determines whether these outcomes are achievable. Read our page on cataract surgery.

What Vision Outcomes and Costs Can Patients Expect?

Clinical outcomes with modern toric IOLs are well established, and the Indian market now offers branded options across different price points.

• Uncorrected distance vision: Published data shows 80 to 90 percent of toric IOL patients achieve 6/12 or better uncorrected distance vision, with the majority reaching 6/6 when biometry and axis alignment are precise. 
• Rotational stability: Modern toric IOLs from Alcon, Zeiss, and Johnson and Johnson rotate less than 5 degrees in the capsular bag in the vast majority of cases. 
• Toric IOL cost in India: Indian market pricing for toric IOLs ranges from Rs 25,000 to Rs 65,000 per eye depending on the brand and toric power required.
• Toric vs limbal relaxing incisions: Limbal relaxing incisions are an alternative for low degrees of astigmatism below 1.25 D. Above this threshold, a toric IOL delivers more predictable and stable correction, particularly for patients with against-the-rule astigmatism where LRI outcomes are less consistent.

Toric IOL outcomes hold up well over time provided the lens stays within 5 degrees of its intended axis and corneal topography was stable at the time of surgery. Patients who develop significant capsular contraction after implantation may need reassessment of axis alignment at the slit lamp. For a full breakdown of treatment costs across IOL types at Claritas, see IOL pricing in Delhi.

Why Choose Claritas Eye Hospital for Toric IOL?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with over 15 years of cataract and anterior segment practice including more than 12,000 cataract procedures. Toric IOL planning at Claritas uses corneal topography, swept-source biometry, and online toric calculators from Alcon and Zeiss to determine axis alignment to the nearest degree before surgery. International patients receive complete pre-operative workup, IOL selection guidance, and discharge summaries structured for handover to their treating ophthalmologist at home. 

Faricimab, sold as Vabysmo, is the first bispecific antibody approved for intravitreal use in ophthalmology. Unlike earlier anti-VEGF agents that block only vascular endothelial growth factor, Faricimab simultaneously targets both VEGF-A and Angiopoietin-2, two proteins that drive retinal vascular instability and fluid leakage. This dual mechanism translates into stronger fluid suppression, longer dosing intervals, and meaningful injection burden reduction for patients managing diabetic macular edema or wet age-related macular degeneration over the long term.

According to Dr. Mayank Bansal, a leading retina specialist at the Best Eye Hospital in Delhi,
“Faricimab represents a meaningful shift in how we manage treatment-resistant DME and wet AMD. By blocking both VEGF-A and Angiopoietin-2 simultaneously, it addresses vascular instability that single-target agents simply cannot reach. ” 

How Does Faricimab Compare to Earlier Anti-VEGF Agents?

The core clinical advantage of Faricimab lies in its dual target mechanism and the extended dosing intervals it supports in both DME and wet AMD.

Cost figures reflect current Indian market pricing and vary by centre. The total annual cost depends on how many injections the individual patient requires once stable intervals are established. For a full overview of all injection agents available at Claritas, see eye injections in Delhi.

Who Benefits Most from Faricimab?

Not every patient with DME or wet AMD needs Faricimab as a first-line choice. Its advantages are most pronounced in specific clinical scenarios.

• Persistent fluid despite prior anti-VEGF therapy: Patients who have received multiple rounds of Aflibercept or Ranibizumab but still show intraretinal or subretinal fluid on OCT are the strongest candidates. 
• DME in patients with poor diabetes control: Angiopoietin-2 levels are particularly elevated in chronically inflamed, poorly controlled diabetic eyes. Faricimab’s anti-Ang-2 action addresses this directly, making it the preferred choice when systemic glucose control remains suboptimal.
• Patients seeking longer intervals: Faricimab supports personalised treat-and-extend protocols reaching up to 16 weeks in both indications. For patients who find monthly or 8-weekly visits burdensome, stable Faricimab treatment can halve annual clinic visits compared to monthly Ranibizumab.
• Bilateral wet AMD or DME: When both eyes need treatment, reaching a 16-week stable interval means both can be treated in the same sitting roughly every four months, significantly reducing total annual procedure visits.
• Treatment-naive patients with high disease activity at baseline: YOSEMITE, RHINE, TENAYA, and LUCERNE trial data showed non-inferior vision gains versus Aflibercept, with a higher proportion achieving fluid-free status at one year. 

The agent’s real-world value is highest when it replaces a protocol that has already shown its ceiling. Switching to Faricimab only makes sense after a proper OCT-guided assessment confirms that the prior agent has genuinely plateaued rather than been under-dosed. For AMD-specific disease background and treatment context, the macular degeneration treatment page covers it.

Why Choose Claritas Eye Hospital for Faricimab ?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with a retina fellowship at UCLA. Over 15 years of vitreoretinal practice managing wet AMD and diabetic macular edema with all major anti-VEGF agents including Faricimab. OCT-guided treat-and-extend protocols are applied individually, with Faricimab considered when persistent fluid or treatment frequency burden points to a dual-pathway approach. International patients receive full coordination including scheduling, accommodation guidance, and discharge summaries formatted for handover to their ophthalmologist at home.

Wet age-related macular degeneration requires long-term anti-VEGF injections to suppress abnormal vessel growth and prevent central vision loss. Two treatment protocols dominate clinical practice: fixed monthly dosing and treat-and-extend, where injection intervals are gradually lengthened based on OCT response. The choice between them affects how many clinic visits a patient needs each year, the total injection burden, and ultimately how well vision is maintained over time.

According to Dr. Mayank Bansal, a leading retina specialist at the Best Eye Hospital in Delhi, “Treat-and-extend has become the preferred protocol for most wet AMD patients because it personalises the dosing interval to each eye’s disease activity rather than applying a fixed schedule regardless of response.”

How Do the Two Protocols Compare?

Both protocols begin with a loading phase of three monthly injections. After that, the approach diverges based on how the retina responds on OCT at each review.

Patients who cannot commit to regular OCT monitoring are better suited to fixed monthly dosing, where the schedule is predictable and adherence is easier to track. For a full overview of the injection agents used across both protocols, read our blog on eye injections.

What Determines Which Protocol Is Right?

Protocol selection is not purely clinical. Follow-up reliability, travel burden, and the agent being used all factor into the decision.

• OCT fluid at loading phase end: Patients who achieve a completely dry macula after three loading injections are strong candidates for treat-and-extend. Those with persistent fluid need close monthly monitoring before any interval extension is attempted.
• Injection agent used: Brolucizumab and Aflibercept both support treat-and-extend well, reaching maximum stable intervals of 12 and 16 weeks respectively. Ranibizumab biosimilars are more commonly run on fixed monthly schedules given their shorter duration of action.
• Patient geography and travel access: For patients travelling from abroad, treat-and-extend meaningfully reduces annual trips. Reaching a stable 12-week interval cuts visits from 13 to roughly 4 to 5 per year.
• Disease severity at presentation: Late presenters with extensive subretinal fluid or pigment epithelial detachment at baseline need longer loading before interval extension is appropriate. Rushing to extend in these eyes risks fluid recurrence and vision loss.
• Bilateral disease: When both eyes require injections, treat-and-extend allows synchronisation so both are treated on the same visit once intervals align, cutting the annual clinic burden significantly.

The protocol that preserves vision best is the one the patient can actually follow consistently over years, not just in the first few months. Pairing the right agent with a dosing schedule the patient can realistically sustain is what drives durable long-term outcomes. For AMD-specific treatment protocols and what to expect at each stage, the macular degeneration treatment page covers the full pathway.

Why Choose Claritas Eye Hospital for Intravitreal Injection ?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with a retina fellowship at UCLA. Over 15 years of vitreoretinal practice managing wet AMD across all stages, with OCT-guided treat-and-extend protocols used as standard across all injection patients. Bilateral AMD cases are synchronised to single-visit scheduling where clinically appropriate to reduce patient burden. International patients receive full coordination including accommodation support, scheduling, and structured discharge summaries for handover to their treating ophthalmologist at home. 

Anti-VEGF injections are the primary treatment for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Four agents dominate clinical practice in India: Aflibercept (Eylea), Ranibizumab (Lucentis and biosimilars), Bevacizumab (Avastin), and Brolucizumab (Pagenax). Each differs in molecular size, dosing interval, available Indian brands, and cost per injection. The right choice depends on disease activity, treatment history, and the patient’s capacity for follow-up visits.

According to Dr. Mayank Bansal, a leading retina specialist at the Best Eye Hospital in Delhi, “No single anti-VEGF agent is universally superior. We individualise the choice based on OCT fluid activity, the patient’s ability to attend follow-up, and the cost burden over a full treatment course, not just per injection.”

How Do the Four Anti-VEGF Agents Compare?

All four agents block vascular endothelial growth factor to reduce abnormal vessel growth and retinal fluid leakage. The differences lie in molecular structure, binding affinity, dosing frequency, and price.

The cost figures above reflect Indian market pricing and vary by centre. Annual treatment cost depends heavily on how many injections the treat-and-extend protocol requires for that individual patient. For the full procedure and drug options available at Claritas, Read our blogs on eye injections.

Which Agent Is Used for Which Condition?

Drug selection is not simply brand preference. Disease type, treatment history, and individual OCT response all feed into the decision.

• Wet AMD with high fluid burden: Brolucizumab and Aflibercept both show strong fluid reduction on OCT. Brolucizumab’s higher molar concentration per dose gives it an edge in patients with persistent subretinal or intraretinal fluid after multiple prior injections with earlier agents.
• Diabetic macular edema: Aflibercept holds strong trial data for DME, particularly in patients with baseline vision of 20/50 or worse. Ranibizumab biosimilars like Razumab are cost-effective alternatives for patients requiring frequent injections over several years.
• Retinal vein occlusion: Both Aflibercept and Ranibizumab carry regulatory approval for branch and central RVO in India. Bevacizumab is widely used off-label given the high injection burden in RVO during the first year of treatment.
• Cost-sensitive patients: Bevacizumab remains the most accessible option at Indian public hospitals and tier-2 centres. Its off-label status does not reduce its real-world efficacy, but patients should receive it only from a surgeon who can compound and administer it under sterile conditions.
• Treatment-naive patients with good follow-up: Aflibercept or Ranibizumab are the standard starting choices, with a switch to Brolucizumab considered when OCT-guided treat-and-extend protocols show persistent fluid at 8-week intervals.

Across all four agents, the decision comes down to OCT disease activity and the patient’s ability to attend follow-up. The agent matters less than the monitoring protocol behind it. For a full overview of conditions treated with these agents, the macular degeneration treatment page covers AMD-specific protocols. 

Why Choose Claritas Eye Hospital for Eylea ? 

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with a retina fellowship at UCLA. Over 15 years of vitreoretinal practice managing wet AMD, DME, and complex retinal vein occlusion with all four major anti-VEGF agents. OCT-guided treat-and-extend protocols are used across all injection patients to minimise total injection burden while protecting vision. International patients receive full support including scheduling, accommodation coordination, and discharge summaries formatted for handover to their ophthalmologist abroad. 

Silicone oil is a temporary tamponade agent placed inside the eye during vitrectomy to hold a detached retina against the eye wall while it heals. It does not dissolve on its own. A planned second surgery removes it once the retina is stable, typically 3 to 6 months after the primary repair. Leaving oil in place beyond this window raises the risk of secondary glaucoma, cataract formation, and corneal band keratopathy.

According to Dr. Mayank Bansal, a leading retina surgeon at the Best Eye Hospital in Delhi, “Silicone oil does its job well in the acute phase, but it was never designed to stay permanently. Timing the removal correctly protects the gains the first surgery made.”

When Is Silicone Oil Removal Recommended?

The decision to remove silicone oil is based on retinal stability, not a fixed calendar date. Several clinical factors determine the right window.

• Retinal attachment confirmed: OCT and indirect ophthalmoscopy must show full retinal reattachment before oil removal is considered. Surgery before the retina is stable risks immediate re-detachment.
• Three to six month standard interval: Most vitreoretinal surgeons plan removal at this point. Complex cases involving proliferative vitreoretinopathy or large breaks may need the oil left in place for 6 to 12 months under close monitoring.
• Raised intraocular pressure: Oil-induced ocular hypertension is a clear signal to bring forward removal. Prolonged pressure elevation damages the optic nerve and can cause permanent field loss if ignored.
• Emulsification: Over time, silicone oil breaks into micro-droplets. Emulsified oil penetrates the anterior chamber, stains the cornea, and accelerates trabecular damage. Early signs of emulsification on slit lamp examination push the timeline forward.
• Cataract development: Oil sitting against the posterior lens capsule accelerates nuclear sclerosis, particularly in phakic eyes.

 Many surgeons combine oil removal with cataract extraction in a single sitting when indicated. For a detailed overview of the primary repair procedure, see retinal detachment surgery at Claritas.

How Is Silicone Oil Removed?

The procedure uses the same 23- or 25-gauge pars plana approach as the original vitrectomy. General or local anaesthesia suits most patients.

• Active extrusion: A flute needle or active aspiration system draws oil out through the infusion and extrusion ports. The surgeon fills the vitreous cavity with balanced salt solution or, where appropriate, a long-acting gas tamponade if any residual risk area exists.
• Simultaneous cataract surgery: When the crystalline lens has opacified, phacoemulsification and IOL implantation are performed in the same session, avoiding a third procedure.
• Operating time: Uncomplicated oil removal runs 30 to 45 minutes. Combined procedures extend this to 60 to 90 minutes.
• Recovery: Most patients notice visual improvement within the first week once the eye adjusts to the absence of oil. Refraction stabilises over 4 to 8 weeks.

Post-operative drops follow the same topical antibiotic and steroid schedule used after the primary repair. For a broader look at the surgical techniques involved in managing complex retinal conditions, the vitrectomy surgery overview explains the full procedure pathway.

Why Choose Claritas Eye Hospital for Silicone Oil Removal ?

Dr. Mayank Bansal is MD (AIIMS), FRCS (Glasgow), FACS, with subspecialty retina training at UCLA. Over 15 years of vitreoretinal practice. More than 5,000 retinal surgeries performed, including complex re-operations for proliferative vitreoretinopathy and silicone oil-related complications. International patients receive full coordination including consultation scheduling, airport transfers, accommodation guidance, and discharge reports structured for seamless handover to their treating ophthalmologist at home.